1. LDN entered clinical practice because of its favorable benefit-to-risk profile

LDN was introduced to Dr. Kim by a patient with an autoimmune condition about 20 years ago. After reviewing the available information, he found there appeared to be significant potential upside with relatively little downside, which led him to begin using it clinically.

Teaching point:
LDN is often considered when the potential benefit appears meaningful and the risk profile is relatively low, especially in chronic inflammatory, autoimmune, and pain-related conditions.

2. LDN is not a miracle cure

LDN can be a powerful tool, but it should not be presented as a cure-all. Its effects vary from person to person, and it often works best as part of a broader integrative treatment plan.

Teaching point:
LDN may help regulate pain, inflammation, immune dysfunction, and neurologic symptoms, but expectations must be realistic.

3. The right question is not “What is the dose?” but “What is the right dose for me?”

A major theme of the lecture was individualized dosing. Standard doses may be too high for some patients, especially those with complex chronic illness, MCAS, long COVID, or severe sensitivity.

Teaching point:
LDN dosing should be individualized. The best starting dose depends on the patient’s tolerance, condition, sensitivity level, and clinical context.

4. Some patients need extremely low doses

Dr. Kim described seeing more patients who cannot tolerate typical LDN doses and may require microgram, nanogram, or even picogram dosing.

Teaching point:
In sensitive patients, especially those with MCAS or post-viral syndromes, “low dose” may need to be much lower than traditional LDN dosing.

5. MCAS may be a key reason some patients are highly sensitive to LDN

The lecture emphasized mast cell activation syndrome as a possible common pathway in patients with Lyme disease, long COVID, chronic inflammation, and complex immune dysfunction.

Teaching point:
Patients with MCAS may have lower endorphin reserve or altered endorphin response, making them more prone to LDN side effects unless dosing is started very low.

6. LDN may work through endorphin modulation

One proposed mechanism of LDN is temporary opioid receptor blockade, which may stimulate the body to produce more endorphins in response.

Teaching point:
LDN is thought to create a temporary endorphin blockade, after which the body may compensate by increasing endorphin production.

7. Endorphin depletion may explain some intolerance patterns

Dr. Kim discussed a growing subset of patients who appear unable to mount a normal endorphin response, especially after COVID or in the setting of MCAS.

Teaching point:
When patients develop anxiety, sleep disruption, tension, or worsening symptoms on LDN, the dose may be too high for their current endorphin reserve.

8. LDN may be useful for neuropathic pain

Dr. Kim described LDN as an excellent tool in his practice for neuropathy, especially trigeminal neuralgia and postherpetic neuralgia.

Teaching point:
LDN may be considered as part of an integrative approach for neuropathic pain conditions, including trigeminal neuralgia and post-shingles nerve pain.

9. Side effects are often managed by stopping and restarting lower

A practical clinical pearl from the lecture was that when patients suspect side effects, they may need to stop LDN until symptoms resolve, then restart at a much lower dose under clinician guidance.

Teaching point:
LDN intolerance often reflects dose mismatch rather than medication failure.

10. Sleep disruption can occur

Some patients experience disrupted sleep whether they take LDN at night, in the morning, or during the day. Dr. Kim connected this pattern to possible endorphin depletion in sensitive patients.

Teaching point:
Sleep disruption on LDN may indicate that the dose is too high and should prompt reassessment.

11. Dry eyes and dry mouth are not typical LDN effects

In response to a question, Dr. Kim stated he was not aware of LDN commonly causing extremely dry eyes and mouth, though any suspected side effect should be approached cautiously.

Teaching point:
If new symptoms appear after starting LDN, consider stopping temporarily and restarting lower, while also evaluating other possible causes.

12. LDN may interact with mast cells and microglia

The lecture noted that LDN is known to affect microglia and may also calm mast cells, which could be relevant in MCAS and neuroinflammatory conditions.

Teaching point:
LDN may have immune-modulating and neuroimmune effects beyond endorphin pathways.

13. LDN may be a foundational tool in integrative medicine

Dr. Kim described LDN as one of his foundational treatments for pain, immune dysfunction, and inflammation.

Teaching point:
LDN can be considered a foundational therapy in selected patients with chronic pain, inflammatory conditions, autoimmune illness, MCAS, and neurologic symptoms.

14. LDN can be secondary support in conditions like endometriosis and adenomyosis

LDN was not presented as a primary treatment for endometriosis or adenomyosis, but it may serve as a secondary tool in the broader treatment strategy.

Teaching point:
LDN may support inflammation and pain regulation, but it should not replace condition-specific evaluation and treatment.

15. LDN and cancer: promising but not proven as treatment

Dr. Kim shared personal and clinical observations related to integrative oncology but emphasized that he was not claiming LDN treats cancer. He referenced suggestive research and clinical experience, including LDN combined with alpha-lipoic acid, but clarified that evidence remains limited.

Teaching point:
LDN should not be promoted as a cancer treatment, but it may have theoretical and investigational relevance in integrative oncology.

16. Organized knowledge is power

The lecture emphasized the importance of patient education, structured communities, and clear rules around medical discussion, especially on platforms like Facebook.

Teaching point:
Patients benefit from organized, responsible education about LDN, especially because online discussions can easily become confusing or misleading.

17. Facebook limitations affect how LDN can be discussed

Dr. Kim explained that Facebook group rules restrict discussion of sourcing, pharmacies, doctors, dosing, and medical advice.

Teaching point:
Educational communities must balance open discussion with platform rules, safety, and professional boundaries.

18. Patients should discuss LDN with their own clinician

Throughout the lecture, Dr. Kim framed his comments as education and clinical experience rather than individualized medical advice.

Teaching point:
LDN decisions should be made with a qualified clinician who understands the patient’s medical history, medications, sensitivities, and goals.

Suggested Closing Message

LDN is not one-size-fits-all. It is a flexible, potentially powerful tool for pain, inflammation, immune dysfunction, MCAS, and neuroimmune conditions, but the key is individualized dosing, realistic expectations, and careful monitoring. For sensitive patients, especially those with MCAS or long COVID, starting extremely low may be essential.